Profile data is unavailable for this security.
About the company
Wave Life Sciences Ltd. is a biotechnology company. The Company is focused on unlocking the potential of RNA medicines (oligonucleotides), or those targeting ribonucleic acid (RNA), to transform human health. Its RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing and RNA interference (RNAi), providing Company with capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity. These programs include WVE-N531, WVE-006 and WVE-003. It is also building a pipeline of novel A-to-I RNA editing oligonucleotides (AIMers).
- Revenue in USD (TTM)53.61m
- Net income in USD-142.52m
- Incorporated2012
- Employees266.00
- LocationWAVE Life Sciences Ltd7 Straits View#12-00, Marina One East Tower 018936SingaporeSGP
- Phone+65 62363388
- Websitehttps://www.wavelifesciences.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Disc Medicine Inc | 0.00 | -103.48m | 1.89bn | 74.00 | -- | 4.04 | -- | -- | -3.97 | -3.97 | 0.00 | 15.73 | 0.00 | -- | -- | 0.00 | -23.74 | -- | -24.88 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -63.22 | -- | -- | -- |
| MannKind Corp | 267.20m | 21.57m | 1.90bn | 414.00 | 97.02 | -- | 67.65 | 7.12 | 0.0711 | 0.0711 | 0.9277 | -0.7612 | 0.6812 | 2.79 | 13.36 | 645,410.60 | 5.50 | -26.07 | 7.00 | -37.80 | 71.91 | 59.68 | 8.07 | -57.61 | 4.17 | 1.89 | 1.77 | -- | 99.42 | 48.17 | 86.34 | -- | 160.47 | -- |
| Beam Therapeutics Inc | 349.64m | -143.59m | 1.95bn | 436.00 | -- | 2.46 | -- | 5.58 | -1.72 | -1.72 | 4.27 | 9.58 | 0.284 | -- | -- | 801,933.50 | -11.67 | -24.54 | -13.84 | -29.26 | -- | -- | -41.07 | -211.96 | -- | -- | 0.00 | -- | 520.01 | -- | 54.16 | -- | 20.78 | -- |
| Mirum Pharmaceuticals Inc | 307.03m | -99.81m | 2.07bn | 311.00 | -- | 8.99 | -- | 6.76 | -2.12 | -2.12 | 6.51 | 4.84 | 0.4657 | 3.83 | 5.28 | 1,162,985.00 | -15.14 | -38.93 | -17.70 | -44.88 | 72.68 | -- | -32.51 | -190.71 | 3.15 | -- | 0.5701 | -- | 141.85 | -- | -20.45 | -- | 21.81 | -- |
| Wave Life Sciences Ltd | 53.61m | -142.52m | 2.09bn | 266.00 | -- | 15.03 | -- | 38.97 | -1.11 | -1.11 | 0.427 | 1.01 | 0.192 | -- | 15.32 | 201,541.40 | -51.04 | -56.98 | -99.07 | -102.38 | -- | -- | -265.84 | -353.20 | -- | -- | 0.00 | -- | 3,005.10 | 51.04 | 64.46 | -- | -35.44 | -- |
| CG Oncology Inc | 684.00k | -78.29m | 2.17bn | 61.00 | -- | 4.07 | -- | 3,171.45 | -1.19 | -1.19 | 0.0104 | 7.95 | 0.0018 | -- | 9.91 | 11,213.12 | -18.93 | -- | -19.63 | -- | -- | -- | -10,578.22 | -- | -- | -- | 0.00 | -- | 6.81 | -- | -54.83 | -- | -- | -- |
| Akero Therapeutics Inc | 0.00 | -237.22m | 2.18bn | 60.00 | -- | 2.94 | -- | -- | -3.75 | -3.75 | 0.00 | 10.61 | 0.00 | -- | -- | 0.00 | -32.66 | -37.73 | -34.35 | -40.13 | -- | -- | -- | -- | -- | -- | 0.0454 | -- | -- | -- | -35.46 | -- | -- | -- |
| Keros Therapeutics Inc | 651.00k | -181.57m | 2.18bn | 160.00 | -- | 3.97 | -- | 3,350.11 | -5.21 | -5.21 | 0.0187 | 13.57 | 0.0014 | -- | -- | 4,786.77 | -40.10 | -35.95 | -42.23 | -38.07 | -- | -- | -27,890.94 | -1,237.26 | -- | -- | 0.00 | -- | -- | -56.77 | -46.15 | -- | 62.57 | -- |
| Azenta Inc | 656.32m | -164.17m | 2.23bn | 3.30k | -- | 1.17 | -- | 3.39 | -2.97 | -2.97 | 12.31 | 38.82 | 0.2633 | 3.23 | 3.71 | -- | -6.59 | -2.07 | -7.18 | -2.31 | 40.13 | 43.11 | -25.01 | -8.76 | 3.50 | -- | -- | -- | -1.32 | -3.41 | -1,174.32 | -- | -- | -- |
| Arrowhead Pharmaceuticals Inc | 19.65m | -538.64m | 2.27bn | 525.00 | -- | 6.87 | -- | 115.66 | -4.65 | -4.65 | 0.1701 | 2.66 | 0.0234 | -- | -- | 37,424.76 | -65.18 | -20.02 | -73.62 | -24.65 | -- | -- | -2,785.85 | -61.79 | -- | -154.93 | 0.00 | -- | -1.03 | 71.68 | -16.59 | -- | 162.38 | -- |
| Ideaya Biosciences Inc | 3.92m | -178.12m | 2.30bn | 124.00 | -- | 1.95 | -- | 586.20 | -2.32 | -2.32 | 0.0515 | 13.67 | 0.0044 | -- | 1.17 | 31,629.03 | -20.09 | -19.17 | -20.87 | -21.05 | -- | -- | -4,541.56 | -244.55 | -- | -- | 0.00 | -- | -54.08 | -- | -92.59 | -- | 6.75 | -- |
| Longboard Pharmaceuticals Inc | 0.00 | -76.34m | 2.33bn | 50.00 | -- | 8.48 | -- | -- | -2.24 | -2.24 | 0.00 | 7.05 | 0.00 | -- | -- | 0.00 | -42.91 | -- | -46.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.84 | -- | -- | -- |
| Soleno Therapeutics Inc | 0.00 | -131.16m | 2.36bn | 33.00 | -- | 8.47 | -- | -- | -3.31 | -3.31 | 0.00 | 6.45 | 0.00 | -- | -- | 0.00 | -72.82 | -53.90 | -82.94 | -61.85 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -62.00 | -- | -- | -- |
Data as of Nov 22 2024. Currency figures normalised to WAVE Life Sciences Ltd's reporting currency: US Dollar USD
47.03%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 30 Sep 2024 | 18.20m | 11.75% |
| Maverick Capital Ltd.as of 30 Sep 2024 | 10.05m | 6.49% |
| Adage Capital Management LPas of 30 Sep 2024 | 9.70m | 6.26% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 6.64m | 4.29% |
| M28 Capital Management LPas of 30 Sep 2024 | 6.16m | 3.98% |
| Driehaus Capital Management LLCas of 30 Sep 2024 | 5.86m | 3.78% |
| Kynam Capital Management LPas of 30 Sep 2024 | 4.90m | 3.16% |
| 683 Capital Management LLCas of 30 Sep 2024 | 4.20m | 2.71% |
| Bellevue Asset Management AGas of 30 Sep 2024 | 4.09m | 2.64% |
| T. Rowe Price Associates, Inc. (IM)as of 30 Sep 2024 | 3.05m | 1.97% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
